149 related articles for article (PubMed ID: 25664505)
1. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
3. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
4. Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.
Makarem YS; Hareedy MS; Hassanien M; Ahmed EA; Hetta HF; Mohamed AA
Pharmacogenomics; 2021 Dec; 22(18):1201-1209. PubMed ID: 34747629
[No Abstract] [Full Text] [Related]
5. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.
Russo PA; Wiese MD; Smith MD; Ahern MJ; Barbara JA; Shanahan EM
Ann Pharmacother; 2013 Mar; 47(3):e15. PubMed ID: 23447478
[TBL] [Abstract][Full Text] [Related]
7. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
[No Abstract] [Full Text] [Related]
8. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.
van der Heijden JW; Oerlemans R; Tak PP; Assaraf YG; Kraan MC; Scheffer GL; van der Laken CJ; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Arthritis Rheum; 2009 Mar; 60(3):669-77. PubMed ID: 19248091
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
10. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
11. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
O'Doherty C; Schnabl M; Spargo L; Cleland LG; James M; Proudman SM; Wiese MD
Pharmacogenomics; 2012 Sep; 13(12):1427-34. PubMed ID: 22966891
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Wiese MD; Alotaibi N; O'Doherty C; Sorich MJ; Suppiah V; Cleland LG; Proudman SM
Pharmacogenomics J; 2014 Aug; 14(4):350-5. PubMed ID: 24394199
[TBL] [Abstract][Full Text] [Related]
13. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy.
Rozin A; Yigla M; Guralnik L; Keidar Z; Vlodavsky E; Rozenbaum M; Nahir AM; Balbir-Gurman A
Clin Rheumatol; 2006 May; 25(3):384-8. PubMed ID: 16211338
[TBL] [Abstract][Full Text] [Related]
15. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
18. Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review.
Keng LT; Lin MW; Huang HN; Chung KP
Medicine (Baltimore); 2016 Jun; 95(26):e4044. PubMed ID: 27368035
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide in clinical practice.
Pinto P; Dougados M
Acta Reumatol Port; 2006; 31(3):215-24. PubMed ID: 17094333
[TBL] [Abstract][Full Text] [Related]
20. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients.
Targońska-Stępniak B; Dryglewska M; Majdan M
Pharmacol Rep; 2010; 62(4):719-25. PubMed ID: 20885012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
